Thiogenesis Therapeutics Corp (TTI.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:TTI -
TTI.CA Key Statistics, Chart & Performance
The current stock price of TTI.CA is 0.59 CAD. In the past month the price decreased by -15.71%. In the past year, price decreased by -1.67%.
TTI.CA Latest News, Press Relases and Analysis
About TTI.CA
Company Profile
Thiogenesis Therapeutics Corp. engages in developing novel drug formulations that act as precursors for rare diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-16. The firm is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.
Company Info
Thiogenesis Therapeutics Corp
4 King Street West, Suite 401
TORONTO ONTARIO CA
Employees: 0
Phone: 16478467766
Thiogenesis Therapeutics Corp / TTI.CA FAQ
Can you describe the business of Thiogenesis Therapeutics Corp?
Thiogenesis Therapeutics Corp. engages in developing novel drug formulations that act as precursors for rare diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-16. The firm is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.
What is the current price of TTI stock?
The current stock price of TTI.CA is 0.59 CAD. The price decreased by -1.67% in the last trading session.
Does Thiogenesis Therapeutics Corp pay dividends?
TTI.CA does not pay a dividend.
What is the ChartMill rating of Thiogenesis Therapeutics Corp stock?
TTI.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is Thiogenesis Therapeutics Corp worth?
Thiogenesis Therapeutics Corp (TTI.CA) has a market capitalization of 30.59M CAD. This makes TTI.CA a Nano Cap stock.
Can you provide the ownership details for TTI stock?
You can find the ownership structure of Thiogenesis Therapeutics Corp (TTI.CA) on the Ownership tab.
TTI.CA Technical Analysis
TTI.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TTI.CA. TTI.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TTI.CA Financial Highlights
Over the last trailing twelve months TTI.CA reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS decreased by -49.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -188.16% | ||
| ROE | -316.78% | ||
| Debt/Equity | 0 |